Our Corporate Values

Strive for Good Science and Strong Processes

MMS is committed to making sound decisions based on strong scientific principles, internal expertise, and applicable regulation. As an organization, MMS emphasizes and values strong internal processes through defining, following, and improving upon the steps that lead to high-quality deliverables.

Value Talent – Find, Attract, Enhance and Retain

MMS recognizes that a talented staff is what drives our business forward. Identifying and attracting top talent and continual training to strengthen core skills are essential to core mission. At MMS, enthusiasm, collaboration, and teamwork is fostered, knowing that a global and diverse talent pool makes the company stronger.

Wow the Customer

MMS believes in delivering value beyond the competition. Each sponsor and researcher that MMS partners with is important and their goals relevant. MMS will strive to exceed their expectations by maintaining a customer focus throughout the project lifecycle, ensuring the customer experience is positive, building trust and forging long-term relationships.

Bring a Sense of Urgency and Leadership (SOUL)

MMS promotes the importance of SOUL through a healthy work environment and as a requirement for providing added value to clients. The SOUL of MMS comes to life as project work is completed on time and as risks and solutions are identified proactively. At MMS, each colleague takes responsibility for the success of every project.

“MMS does a great job of supporting colleague development through extensive training, job shadowing, mentoring, and teamwork activities.”
TEAM LEAD ON MENTORING

Suggested For You

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval

webinar

September 12th, 2024

No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology

regulatory intelligence

August 9th, 2024

FDA Updates 2024 Language Access Plan

regulatory intelligence

August 3rd, 2024

EMA Launches New Pilot Program for Orphan Medical Devices

perspectives

July 30th, 2024

The Critical Role of Quality Control (QC) – Medical Writing and Beyond

regulatory intelligence

July 26th, 2024

Key Decision Points for Recent Oncology Approvals

regulatory intelligence

July 24th, 2024

Comments Open for Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products

perspectives

July 23rd, 2024

PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma

news

July 17th, 2024

Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization